Cleveland Cord Blood Center
BiotechCleveland Cord Blood Center is a biotechnology company with 1 FDA-approved products.
Cleveland Cord Blood Center's Key Drugs
Cleveland Cord Blood Center's core commercial portfolio centers on Clevecord — its most strategically important drugs approved in the last 15 years.
Cleveland Cord Blood Center's Recent FDA Approvals
New NDA/BLA approvals for Cleveland Cord Blood Center over the last two years — novel drugs only, excluding generics and label supplements.
Cleveland Cord Blood Center's Therapeutic Areas
Disease areas where Cleveland Cord Blood Center has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Cleveland Cord Blood Center Pipeline Snapshot
Active clinical trials for Cleveland Cord Blood Center across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Clevecord leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2016-08-31
- Latest
- 2016-08-31
- Applications
- 1